Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Price target reduced to €57.95

0

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) had its price target reduced by research analysts at Berenberg Bank from €76.70 ($78.27) to €57.95 ($59.13) in a research report released Wednesday to clients and investors, Fly reports.

Several other brokerages have also recently published reports on FMS. Truist Financial cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating for the company in a Wednesday, June 22 report. StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong buy” rating to a “buy” rating in a Friday, July 15 report. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from an “underperforming” rating to a “buy” rating and raised its share price target from $30.30 to 33 $.70 in a Monday, June 27 report. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research report. Finally, JPMorgan Chase & Co. lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a report research on Monday August 1st. One analyst rated the stock with a sell rating, seven issued a hold rating and four assigned the company a buy rating. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $45.83.

Fresenius Medical Care AG & Co. KGaA trades up 0.5%

NYSE FMS opened at $18.85 on Wednesday. The company has a fifty-day simple moving average of $23.68 and a two-hundred-day simple moving average of $29.31. The stock has a market capitalization of $11.05 billion, a P/E ratio of 12.02, a P/E/G ratio of 0.92 and a beta of 1.02. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.16 and a 12-month high of $40.85. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt ratio of 0.47.

Hedge funds weigh on Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Pzena Investment Management LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 47.6% during the fourth quarter. Pzena Investment Management LLC now owns 9,459,446 shares of the company worth $307,054,000 after acquiring an additional 3,051,672 shares in the last quarter. First Trust Advisors LP increased its stake in Fresenius Medical Care AG & Co. KGaA by 15.1% during the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company worth $62,496,000 after purchasing an additional 252,768 shares during the period. Bank of America Corp DE increased its stake in Fresenius Medical Care AG & Co. KGaA by 27.9% during the first quarter. Bank of America Corp DE now owns 1,083,689 shares of the company worth $36,499,000 after purchasing an additional 236,459 shares during the period. Cambiar Investors LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 18.3% during the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company worth $45,935,000 after purchasing an additional 210,819 shares during the period. Finally, Invesco Ltd. increased its stake in Fresenius Medical Care AG & Co. KGaA by 54.0% during the fourth quarter. Invesco Ltd. now owns 376,173 shares of the company worth $12,211,000 after purchasing an additional 131,870 shares during the period. 4.73% of the shares are currently held by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Further reading

The Fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

Comments are closed.